CATX (Perspective Therapeutics) Net Income (Continuing Operations): $-116.63 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CATX Perspective Therapeutics Inc CATX
30 GF Score
Price $3.12
! 2 Warning Signs
View Full Analysis

What is Perspective Therapeutics Net Income (Continuing Operations)?

Perspective Therapeutics CATX +0.65% 30 Net Income (Continuing Operations) is $-116.63 Mil as of Jun. 2026. GuruFocus rates CATX with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Perspective Therapeutics's Net Income (Continuing Operations) for the three months ended in Jun. 2026 was $-26.98 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 was $-116.63 Mil.

Perspective Therapeutics  (AMEX:CATX) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Perspective Therapeutics Net Income (Continuing Operations) Related Terms

Perspective Therapeutics Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Perspective Therapeutics's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Perspective Therapeutics Net Income (Continuing Operations) Chart

Perspective Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.39 -7.27 -37.46 -78.33 -103.64

Perspective Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.00 -25.97 -37.49 -26.19 -26.98
CATX
30GF Score
Perspective Therapeutics Inc CATX
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Perspective Therapeutics Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-116.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of $-116.63 Mil mean?
Perspective Therapeutics (CATX) has a Net Income (Continuing Operations) of $-116.63 Mil as of Jun. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Perspective Therapeutics and its competitors.
Is Perspective Therapeutics' Net Income (Continuing Operations) too high?
Perspective Therapeutics' current Net Income (Continuing Operations) is $-116.63 Mil. Overall, Perspective Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Perspective Therapeutics' Net Income (Continuing Operations) compare to VMD and MOBI?
Perspective Therapeutics' Net Income (Continuing Operations) of $-116.63 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Medical Devices & Instruments company?
A good Net Income (Continuing Operations) depends on the Medical Devices & Instruments industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Perspective Therapeutics and its competitors. Perspective Therapeutics's current Net Income (Continuing Operations) is $-116.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perspective Therapeutics stock overvalued right now?
Perspective Therapeutics (CATX) has a current Net Income (Continuing Operations) of $-116.63 Mil. The current Net Income (Continuing Operations) is $-116.63 Mil. Perspective Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Perspective Therapeutics (CATX), the current Net Income (Continuing Operations) is $-116.63 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Perspective Therapeutics Business Description

Other Exchanges AAJ0:Germany
Address 2401 Elliott Avenue, Suite 320, Seattle, WA, USA, 98121
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
30GF Score

Get the complete analysis for CATX

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.12
Price